Menu
Back to User profile » Dr William A Fahy
Papers published by Dr William A Fahy:
Terms and Definitions Used to Describe Recurrence, Treatment Failure and Recovery of Acute Exacerbations of COPD: A Systematic Review of Observational Studies
Meeraus WH, DeBarmore BM, Mullerova H, Fahy WA, Benson VS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3487-3502
Published Date: 24 December 2021
Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study
Fahy WA, Homayoun-Valiani F, Cahn A, Robertson J, Templeton A, Meeraus WH, Wilson R, Lowings M, Marotti M, West SL, Tabberer M, Hessel EM
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1637-1646
Published Date: 3 June 2021
Predicting Re-Exacerbation Timing and Understanding Prolonged Exacerbations: An Analysis of Patients with COPD in the ECLIPSE Cohort
Meeraus WH, Mullerova H, El Baou C, Fahey M, Hessel EM, Fahy WA
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:225-244
Published Date: 5 February 2021
Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
Singh S, Maltais F, Tombs L, Fahy WA, Vahdati-Bolouri M, Locantore N, Riley JH
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:203-215
Published Date: 8 January 2018
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
Kerwin EM, Kalberg CJ, Galkin DV, Zhu C, Church A, Riley JH, Fahy WA
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:745-755
Published Date: 24 February 2017
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1413-1424
Published Date: 24 June 2016
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD
Siler TM, Donald AC, O’Dell D, Church A, Fahy WA
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:971-979
Published Date: 9 May 2016
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, Trivedi R
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:719-730
Published Date: 7 April 2016